Explore a selection of our essential drug information below, or:
Identification
- Summary
Enmetazobactam is a beta-lactamase inhibitor used to treat complicated urinary tract infections in combination with cefepime.
- Brand Names
- Exblifep
- Generic Name
- Enmetazobactam
- DrugBank Accession Number
- DB18716
- Background
Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor.1 Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious infections.3
The combination product of enmetazobactam and cefepime was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.5 Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Enmetazobactam (DB18716)
- Weight
- Average: 314.32
Monoisotopic: 314.068490741 - Chemical Formula
- C11H14N4O5S
- Synonyms
- (2s,3s,5r)-3-methyl-3-((3-methyltriazol-3-ium-1-yl)methyl)-4,4,7-trioxo-4^6-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate
- 1h-1,2,3-triazolium, 3-(((2s,3s,5r)-2-carboxy-3-methyl-4,4-dioxido-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-3-yl)methyl)-1-methyl-, inner salt
- External IDs
- AAI 101
- AAI-101
- AAI101
- OCID-5090
Pharmacology
- Indication
In combination with cefepime, enmetazobactam is indicated for the treatment of adults with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible microorganisms.4
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Complicated urinary tract infection Combination Product in combination with: Cefepime (DB01413) •••••••••••• ••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Enmetazobactam is an antibacterial agent that is active against most gram-positive and gram-negative bacteria.4
- Mechanism of action
Extended-spectrum beta-lactamases (ESBLs) are a group of bacterial serine beta-lactamases that hydrolyze third-generation cephalosporins (3GC), leading to the development of 3GC-resistant bacteria.1,2 When used in combination with cefepime, enmetazobactam protects cefepime from degradation by ESBLs and prevents antibiotic resistance.4
Target Actions Organism AExtended-spectrum beta-lactamase PER-1 inhibitorPseudomonas aeruginosa ABeta-lactamase inhibitorStaphylococcus aureus - Absorption
The mean (SD) Cmax is 19.8 (6.3) µg/mL in patients with cUTI and eGFR greater than or equal to 60 mL/min. The mean AUC0-last is 75.3 (30.8) μgxh/mL.4
- Volume of distribution
Mean (SD) steady state volume of distribution (Vss) is 25.26 (9.97) L in patients with cUTI and eGFR greater than or equal to 60 mL/min..4
- Protein binding
The percent protein binding of enmetazobactam is negligible.4
- Metabolism
Enmetazobactam is minimally metabolized.4
- Route of elimination
About 90% of enmetazobactam is excreted unchanged in urine.4
- Half-life
The mean (SD) half-life is 2.6 (1.1) hours in patients with cUTI and eGFR greater than or equal to 60 mL/min.4
- Clearance
The mean (SD) clearance is 7.6 (2.9) L/h in patients with cUTI and eGFR greater than or equal to 60 mL/min.4
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
There is limited information on the acute toxicity (LD50) or overdose of enmetazobactam. Symptoms of overdose may include encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), myoclonus, seizures, neuromuscular excitability and nonconvulsive status epilepticus. Enmetazobactam can be removed by hemodialysis.4
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcenocoumarol The risk or severity of bleeding can be increased when Enmetazobactam is combined with Acenocoumarol. Ambroxol The risk or severity of methemoglobinemia can be increased when Enmetazobactam is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Enmetazobactam is combined with Articaine. BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Enmetazobactam. Benzocaine The risk or severity of methemoglobinemia can be increased when Enmetazobactam is combined with Benzocaine. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Exblifep Enmetazobactam (0.5 g/1) + Cefepime hydrochloride (2 g/1) Injection, powder, for solution Intravenous Allecra Therapeutics SAS 2024-02-28 Not applicable US 
Exblifep Enmetazobactam (0.5 g) + Cefepime hydrochloride (2 g) Injection, powder, for solution Intravenous Advanz Pharma Limited 2024-07-10 Not applicable EU 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Pseudomonas aeruginosa
- Escherichia coli
- Serratia marcescens
- Proteus mirabilis
- Providencia stuartii
- Providencia rettgeri
- Enterobacter cloacae
- Klebsiella pneumoniae
- Klebsiella oxytoca
- Citrobacter freundii
- Klebsiella aerogenes
Chemical Identifiers
- UNII
- 80VUN7L00C
- CAS number
- 1001404-83-6
- InChI Key
- HFZITXBUTWITPT-YWVKMMECSA-N
- InChI
- InChI=1S/C11H14N4O5S/c1-11(6-14-4-3-13(2)12-14)9(10(17)18)15-7(16)5-8(15)21(11,19)20/h3-4,8-9H,5-6H2,1-2H3/t8-,9+,11-/m1/s1
- IUPAC Name
- 1-{[(2S,3S,5R)-2-carboxylato-3-methyl-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptan-3-yl]methyl}-3-methyl-1H-1,2,3-triazol-3-ium
- SMILES
- [H][C@@]12CC(=O)N1[C@@H](C([O-])=O)[C@](C)(CN1C=C[N+](C)=N1)S2(=O)=O
References
- General References
- Bernhard F, Odedra R, Sordello S, Cardin R, Franzoni S, Charrier C, Belley A, Warn P, Machacek M, Knechtle P: Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model. Antimicrob Agents Chemother. 2020 May 21;64(6):e00078-20. doi: 10.1128/AAC.00078-20. Print 2020 May 21. [Article]
- Paterson DL, Bonomo RA: Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005 Oct;18(4):657-86. doi: 10.1128/CMR.18.4.657-686.2005. [Article]
- Rupp ME, Fey PD: Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs. 2003;63(4):353-65. doi: 10.2165/00003495-200363040-00002. [Article]
- FDA Approved Drug Products: EXBLIFEP (cefepime and enmetazobactam) for injection, for intravenous use [Link]
- Contemporary OB/GYN: FDA approves enmetazobactam for treatment of cUTIs [Link]
- External Links
- ChemSpider
- 68025157
- 2675985
- ChEMBL
- CHEMBL4458276
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Urinary Tract Infection 1 somestatus stop reason just information to hide 2 Completed Treatment Urinary Tract Infection 1 somestatus stop reason just information to hide 2 Recruiting Treatment Complicated Urinary Tract Infection 1 somestatus stop reason just information to hide 1 Completed Other Healthy Volunteers (HV) 2 somestatus stop reason just information to hide 1 Completed Other PK in Patients With Various Degrees of Renal Impairment 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Intravenous - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US7687488 No 2007-12-03 2027-12-03 US US11124526 No 2014-11-07 2034-11-07 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -4.6 Chemaxon pKa (Strongest Acidic) 2.09 Chemaxon pKa (Strongest Basic) 2.83 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 116.28 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 111.61 m3·mol-1 Chemaxon Polarizability 28.34 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
- Kind
- Protein
- Organism
- Pseudomonas aeruginosa
- Pharmacological action
- Yes
- Actions
- Inhibitor
- Curator comments
- This is a representative organism. Enmetazobactam works against many gram-negative and gram-positive bacteria.
- General Function
- Not Available
- Specific Function
- beta-lactamase activity
- Gene Name
- per1
- Uniprot ID
- P37321
- Uniprot Name
- Extended-spectrum beta-lactamase PER-1
- Molecular Weight
- 33572.575 Da
References
- FDA Approved Drug Products: EXBLIFEP (cefepime and enmetazobactam) for injection, for intravenous use [Link]
- Kind
- Protein
- Organism
- Staphylococcus aureus
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Not Available
- Specific Function
- beta-lactamase activity
- Gene Name
- blaZ
- Uniprot ID
- P00807
- Uniprot Name
- Beta-lactamase
- Molecular Weight
- 31348.98 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- A cytochrome P450 monooxygenase involved in the metabolism of fatty acids (PubMed:10553002, PubMed:18577768). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:10553002, PubMed:18577768). Catalyzes the hydroxylation of carbon-hydrogen bonds. Hydroxylates fatty acids specifically at the omega-1 position displaying the highest catalytic activity for saturated fatty acids (PubMed:10553002, PubMed:18577768). May be involved in the oxidative metabolism of xenobiotics (Probable)
- Specific Function
- 4-nitrophenol 2-monooxygenase activity
- Gene Name
- CYP2E1
- Uniprot ID
- P05181
- Uniprot Name
- Cytochrome P450 2E1
- Molecular Weight
- 56848.42 Da
References
- FDA Approved Drug Products: EXBLIFEP (cefepime and enmetazobactam) for injection, for intravenous use [Link]
Drug created at February 26, 2024 21:59 / Updated at August 26, 2024 19:23